15 Sep Porton Advanced Solutions
Andrew Chen, CEO
Oct. 7 | 5:00pm | FLW Ballroom F
Cranbury, NJ
(Private)
Porton Advanced is a leading cell and gene therapy CRO/CDMO. We deliver a wide range of products and services across research-grade and GMP-grade categories. As of today, we have successfully supported our clients in securing 19 global IND approvals, including 5 FDA, and have 7 Phase I/II ATMP projects.
Porton Advanced has developed specialized CRO and CDMO platforms focusing on plasmids, viral vectors, cell therapy CMC services (including in vivo and ex vivo CAR-T, CAR-NK, HSC, iPSC, exosomes, etc) and nucleic acid therapies (mRNA, circRNA, saRNA, and LNP formulation). We support different stages of drug development, from early research, investigator-initiated trials (IIT), investigational new drug (IND) applications, clinical trials, new drug applications (NDA), to commercialization. Our unique position as a U.S-China company has allowed Porton Advanced has support the successful transition of several overseas clinical-stage pipelines into China.
